Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Channel Therapeutics Corporation (CHRO) is a biotechnology firm focused on developing innovative therapies for various medical conditions, leveraging its proprietary drug delivery systems. The company operates primarily in the United States and is currently in the preclinical stage of its product pipeline, which includes cannabinoid-based therapies aimed at treating chronic pain and neurological disorders.
Channel Therapeutics relies on collaborations and partnerships with larger pharmaceutical firms for funding and distribution of its drug candidates. The company has potential pricing power due to its unique delivery systems that enhance the efficacy of cannabinoids, setting it apart from competitors.
Progress in clinical trials for cannabinoid therapies
Partnership announcements with larger pharmaceutical companies
Regulatory approvals for drug candidates
Market sentiment towards the biotechnology sector
Regulatory changes affecting the approval process for cannabinoid-based therapies
Technological disruption in drug delivery systems
Emergence of alternative therapies for chronic pain and neurological disorders
Increased competition from established pharmaceutical companies entering the cannabinoid space
High cash burn rate with no current revenue generation
Potential liquidity issues if funding is not secured
low - The demand for biotechnology products is generally less sensitive to economic cycles, as healthcare spending remains relatively stable.
Moderate - Rising interest rates could increase the cost of capital for funding R&D, potentially impacting the company's ability to finance its operations.
minimal - The company is not heavily reliant on credit markets due to its current lack of revenue.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has shown significant volatility, with a 1-year return of -87.4%.
